| Date | Form | Description | Docs | XBRL | Pages |
| 01/09/18 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
148 |
| 12/12/17 | 8-K | Current report filing |
|
3 | |
| 11/22/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
3 | |
| 11/17/17 | 8-K | Current report filing |
|
48 | |
| 11/17/17 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
45 | |
| 10/26/17 | EFFECT | Notice of Effectiveness |
|
1 | |
| 10/24/17 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 10/23/17 | UPLOAD | SEC-generated letter |
|
2 | |
| 10/23/17 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
Latest News & Events
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants
Read More...Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
Read More...Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Read More...